Evidence map›Paper›PMID 41317095›Full record

ArticleCancer medicine2025

Second Primary Lung Cancer Associated With Family History of Lung Cancer.

Frantisek Zitricky, Kristina Sundquist, Jan Sundquist, Asta Försti, Akseli Hemminki, Kari Hemminki

Erratum issuedAbstract read
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Frantisek ZitrickyBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.ORCID https://orcid.org/0000-0001-7600-7143
Kristina SundquistCenter for Primary Health Care Research, Lund University, Malmö, Sweden.
Jan SundquistCenter for Primary Health Care Research, Lund University, Malmö, Sweden.
Asta FörstiHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Akseli HemminkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0001-7103-8530
Kari HemminkiBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.ORCID https://orcid.org/0000-0002-2769-3316

Funding

Finnish Cancer OrganizationsHelsinki University Central HospitalJane and Aatos Erkko FoundationSigrid Juselius Foundation
6 · The paper itself

Abstract

backgroundFamilial clustering of initial primary lung cancer (IPLC) may be related to shared smoking habits, other environmental exposures and hereditary factors, but whether familial risk also influences the risk of second primary LC (SPLC) is not well known. We aimed to carry out a family study between first-degree relatives on SPLCs in Sweden.

methodsPopulation data on Swedish family relationships and the diagnosed cancers were obtained from the national registers from 1961 to 2021. IPLC was diagnosed in 54,429 patients of whom 534 were diagnosed with SPLC. Familial risk was assessed through the standardized incidence ratio (SIR with 95% confidence interval) adjusted for several potential confounders, including sex, age, calendar period, educational level and geographic region. Familial risks were analyzed by type of proband, histology and sex. In addition, we estimated the effect of family history on the cumulative proportion of patients developing SPLC by sex and histology.

resultsThe estimated SIR for SPLC was 3.98 in patients without family history and 5.24 among those with a history of lung cancer in first-degree relatives. The SIR values depended on the histology of IPLC and of SPLC, with the highest SIRs for concordant histologies. For the adenocarcinoma-adenocarcinoma sequence, SIR estimates were 5.60 and 7.51 for non-familial and familial patients, respectively. The familial risks were further modulated by sex and type of affected relative, with the highest SIR for females with affected mothers (9.14).

conclusionsThe results showed a positive association of family history of LC with risk of SPLC on top of high risk for SPLC in non-familial patients. The risks differed by sex, histology and type of affected relative. The data on family history of LC should alert about surveillance for SPLC and may be used in future risk stratification when eligibility for population screening is considered.

Indexed as

Lung NeoplasmsNeoplasms, Second PrimaryAdultAgedAged, 80 and overFemaleGenetic Predisposition to DiseaseHumansIncidenceMaleMiddle AgedRegistriesRisk FactorsSwedenadenocarcinomaincidence trendprobandsibling risk

Identifiers

PMID41317095
PMCPMC12664089

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.